BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

746 related articles for article (PubMed ID: 10500524)

  • 21. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.
    Blaise D; Attal M; Reiffers J; Michallet M; Bellanger C; Pico JL; Stoppa AM; Payen C; Marit G; Bouabdallah R; Sotto JJ; Rossi JF; Brandely M; Hercend T; Maraninchi D
    Eur Cytokine Netw; 2000 Mar; 11(1):91-8. PubMed ID: 10705305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of acute lymphoblastic leukemia in adults with seven-drug induction therapy and intensive consolidation with or without autologous stem cell transplantation followed by maintenance therapy. Experience of a single center].
    Doubek M; Mayer J; Korístek Z; Protivánková M; Brychtová Y; Oborilová A; Král Z; Klabusay M; Tomíska M; Buchtová I; Vorlícek J
    Cas Lek Cesk; 2002 Mar; 141(4):122-6. PubMed ID: 12046256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant.
    de Lima M; van Besien K; Gajewski J; Khouri I; Andersson B; Korbling M; Champlin R; Giralt S
    Bone Marrow Transplant; 2000 Aug; 26(3):333-8. PubMed ID: 10967575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission: 50 cases from a single center.
    Powles R; Mehta J; Singhal S; Horton C; Tait D; Milan S; Pollard C; Lumley H; Matthey F; Shirley J
    Bone Marrow Transplant; 1995 Aug; 16(2):241-7. PubMed ID: 7581142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia.
    van Agthoven M; Groot MT; Verdonck LF; Löwenberg B; Schattenberg AV; Oudshoorn M; Hagenbeek A; Cornelissen JJ; Uyl-de Groot CA; Willemze R
    Bone Marrow Transplant; 2002 Aug; 30(4):243-51. PubMed ID: 12203141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Bone marrow transplantation in the treatment of acute leukemias].
    Moiseev SI; Ganapiev AA; Abdulkadyrov KM
    Ter Arkh; 1996; 68(12):8-10. PubMed ID: 9054052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation.
    Sobecks RM; Le Beau MM; Anastasi J; Williams SF
    Bone Marrow Transplant; 1999 Jun; 23(11):1161-5. PubMed ID: 10382956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-2 therapy after allogeneic bone marrow transplantation for acute myelocytic leukemia: studies in a relevant rat model for AML.
    Kloosterman TC; Martens AC; Osterwalder B; Hagenbeek A
    Bone Marrow Transplant; 1994 Dec; 14(6):965-73. PubMed ID: 7711675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease- or therapy-related bone marrow damage cannot be overcome by changes in stem cell source or dose in allogeneic transplantation.
    Novotny JR; Rosenthal C; Elmaagacli AH; Dürig J; Beelen DW; Dührsen U
    Eur J Haematol; 2004 Jul; 73(1):1-9. PubMed ID: 15182331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hematopoietic stem cell transplantation in childhood leukemias].
    Kawano Y; Takaue Y
    Gan To Kagaku Ryoho; 1999 Sep; 26(10):1415-23. PubMed ID: 10500528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The role of cost analysis in the evaluation of the development of medical technology. The case of allogenic stem-cell transplantation].
    Groot MT; van Agthoven M; Löwenberg B; Willemze R; Uyl-de Groot CA
    Ned Tijdschr Geneeskd; 2004 Mar; 148(10):480-4. PubMed ID: 15042895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hematopoietic stem cell transplantation: principles and practice].
    Burdach S; Nürnberger W; Göbel U
    Praxis (Bern 1994); 1996 Jun; 85(23):741-8. PubMed ID: 8693241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
    Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V;
    Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bone marrow transplantation versus maintenance chemotherapy for adult acute leukemia in first remission].
    Suzuki R; Iida H; Taji H; Murata M; Sugihara T; Minami S; Kodera Y
    Rinsho Ketsueki; 1996 Dec; 37(12):1362-70. PubMed ID: 8997123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogeneic versus autologous versus peripheral stem cell transplantation in CR1 pediatric AML patients: a single center experience.
    Anak S; Saribeyoglu ET; Bilgen H; Unuvar A; Karakas Z; Devecioglu O; Agaoglu L; Gedikoglu G
    Pediatr Blood Cancer; 2005 Jun; 44(7):654-9. PubMed ID: 15700262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of chimerism and early engraftment after allogeneic peripheral blood stem cell or bone marrow transplantation by short tandem repeats.
    Frankel W; Chan A; Corringham RE; Shepherd S; Rearden A; Wang-Rodriguez J
    Am J Hematol; 1996 Aug; 52(4):281-7. PubMed ID: 8701946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transplantation of haematopoietic stem cells derived from cord blood, bone marrow or peripheral blood: a single centre matched-pair analysis in a heterogeneous risk population.
    Schönberger S; Niehues T; Meisel R; Bernbeck B; Laws HJ; Kögler G; Enzmann J; Wernet P; Göbel U; Dilloo D
    Klin Padiatr; 2004; 216(6):356-63. PubMed ID: 15565551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.
    Tsimberidou AM; Stavroyianni N; Viniou N; Papaioannou M; Tiniakou M; Marinakis T; Skandali A; Sakellari I; Yataganas X;
    Cancer; 2003 Apr; 97(7):1721-31. PubMed ID: 12655529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autologous PBSC transplant for late onset AML after mafosfamide-purged and TBI-containing autologous BMT.
    Bassan R; Cortelazzo S; Rambaldi A; Cornelli P; Borleri G; Bellavita P; Biondi A; Barbui T
    Bone Marrow Transplant; 1995 May; 15(5):791-3. PubMed ID: 7670409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.